Network meta-analysis of survival data with fractional polynomials

BMC Medical Research Methodology

Volumn 11, Issue , 2011, Pages

  Jansen, Jeroen P ^a  

^a MAPI VALUES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; META ANALYSIS; MORTALITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; STATISTICS; SURVIVAL; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; HUMANS; KAPLAN-MEIER ESTIMATE; MODELS, STATISTICAL; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79955660223     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-11-61     Document Type: Article

References (29)

1. Borrowing strength from external trials in a meta-analysis. JPT Higgins A Whitehead, Statistics in Medicine 1996 15 2733 2749 10.1002/(SICI)1097- 0258(19961230)15:24<2733::AID-SIM5623.0.CO;2-0 8981683 (Pubitemid 27011054)
2. Network meta-analysis for indirect treatment comparisons. T Lumley, Statistics in Medicine 2002 21 2313 2324 10.1002/sim.1201 12210616
3. Combination of direct and indirect evidence in mixed treatment comparisons. G Lu AE Ades, Statistics in Medicine 2004 23 3105 3124 10.1002/sim.1875 15449338 (Pubitemid 39334902)
4. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. DM Caldwell AE Ades JPT Higgins, British Medical Journal 2005 331 897 900 10.1136/bmj.331.7521.897 16223826 (Pubitemid 41502718)
5. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling (with discussion). P Royston DG Altman, Applied Statistics 1994 43 429 467 10.2307/2986270
6. Additive and multiplicative covariate regression models for relative survival incorporating fractional polynomials for time-dependent effects. PC Lambert LK Smith DR Jones JL Botha, Statistics in Medicine 2005 24 3871 3885 10.1002/sim.2399 16320260 (Pubitemid 43115736)
7. Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer. N Bossard F Descotes AG Bremond Y Bobin P De Saint Hilaire F Golfier,, et al. Breast Cancer Research and Treatment 2003 82 47 59 10.1023/B:BREA.0000003919.75055.e8 14672403 (Pubitemid 37476019)
8. Dynamic Cox modelling based on fractional polynomials: time-variations in gastric cancer prognosis. U Berger J Schafer K Ulm, Statistics in Medicine 2003 22 1163 1180 10.1002/sim.1411 12652560 (Pubitemid 36394940)
9. Flexible meta-regression functions for modeling aggregate dose response data, with an application to alcohol and mortality. V Bagnardi A Zambon P Quatto G Corrao, American Journal of Epidemiology 2004 159 1077 1086 10.1093/aje/kwh142 15155292
10. Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. W Sauerbrei P Royston, JRSSA 1999 162 71 94
11. A new proposal for multivariable modelling of time-varying effects in survival data based on fractional polynomial time-transformation. W Sauerbrei P Royston M Look, Biom J 2007 9 453 473
12. Assessing evidence inconsistency in mixed treatment comparisons. G Lu AE Ades, J Am Stat Assoc 2006 101 447 459 10.1198/016214505000001302 (Pubitemid 43972289)
13. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. NJ Cooper AJ Sutton D Morris AE Ades NJ Welton, Stat Med 2009 28 1861 81 10.1002/sim.3594 19399825
14. Information theory and an extension of the maximum likelihood principle. H Akaike, Second International Symposium on Information Theory 1973 1 267 281
15. The direct use of likelihood for significance testing. AP Dempster, Statistics and Computing 1997 7 247 252 10.1023/A:1018598421607 (Pubitemid 128000163)
16. Bayesian measures of model complexity and fit. DJ Spiegelhalter NG Best BP Carlin A van der Linde, Journal of the Royal Statistical Society, Series B 2002 64 583 639 10.1111/1467-9868.00353
17. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. JR Molina P Yang SD Cassivi SE Schild AA Adjei, Mayo Clin Proc 2008 83 584 94 10.4065/83.5.584 18452692 (Pubitemid 351720831)
18. Platinum-based second-line treatment in non-small-cell lung cancer: an old new kid on the block? LH De Lima Arajo CG Ferreira, J Clin Oncol 2010 10 28 24 5
19. Gefitinib IRESSA in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. A Chang P Parikh S Thongprasert E Tan R Perng D Ganzon,, et al. Journal of thoracic oncology: official publication of theInternational Association for the Study of Lung Cancer 2006 1 847 55 (Pubitemid 47181391)
20. Phase II, open-label, randomized study SIGN of single-agent gefitinib IRESSA or docetaxel as second-line therapy in patients with advanced stage IIIb or IV non-small-cell lung cancer. T Cufer E Vrdoljak R Gaafar I Erensoy K Pemberton SIGN Study Group, Anti-cancer drugs 2006 17 401 9 10.1097/01.cad. 0000203381.99490.ab 16549997 (Pubitemid 44309982)
21. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. N Hanna FA Shepherd FV Fossella JR Pereira F De Marinis J von Pawel,, et al. J Clin Oncol 2004 22 1589 97 10.1200/JCO.2004.08.163 15117980 (Pubitemid 41079796)
22. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer INTEREST: a randomised phase III trial. E Kim V Hirsh T Mok M Socinski R Gervais Y Wu,, et al. Lancet 2008 372 1809 18 10.1016/S0140-6736(08)61758-4 19027483
23. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. D Lee K Park J Kim J Lee S Shin J Kang,, et al. Clinical cancer research 2010 16 1307 14 10.1158/1078-0432.CCR-09-1903 20145166
24. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. R Maruyama Y Nishiwaki T Tamura N Yamamoto M Tsuboi K Nakagawa,, et al. Journal of clinical oncology: official journal of the AmericanSociety of Clinical Oncology 2008 26 4244 52
25. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. FA Shepherd J Dancey R Ramlau,, et al. J Clin Oncol 2000 18 2095 103 10811675 (Pubitemid 30324363)
26. Bayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis. AE Ades M Sculpher AJ Sutton K Abrams N Cooper N Welton G Lu, Pharmacoeconomics 2006 24 1 19 10.2165/00019053-200624010-00001 17266384 (Pubitemid 43197227)
27. Bayesian approaches to clinical trials and health-care evaluations. DJ Spiegelhalter KR Abrams JP Myles, Chichester: John Wiley & Sons 2004 80 85
28. Bayesian approaches to clinical trials and health-care evaluations. DJ Spiegelhalter KR Abrams JP Myles, Chichester: John Wiley & Sons 2004 286
29. D Spiegelhalter A Thomas N Best D Lunn, WinBUGS User Manual: Version 1.4 MRC Biostatistics Unit: Cambridge 2003